EU begins review of Bavarian Nordic monkeypox vaccine

The European Union drug regulator said on Tuesday it has launched a review to expand the use of Bavarian Nordic’s smallpox vaccine to also prevent monkeypox disease.
The Danish biotech’s Imvanex vaccine is approved for smallpox in Europe, but is intended for off-label use to treat cases of monkeypox.
As of last week, more than 3,400 confirmed cases of monkey pox and one death were reported to the World Health Organization, the majority of which were from Europe.
The Bavarian Nordic shot has already been approved for both smallpox and monkeypox in the United States, where it is called Jynneos.
The decision to launch the EU review is based on results of laboratory studies suggesting that the vaccine triggers the production of antibodies targeting the monkeypox virus, the European Medicines Agency said.
The regulator also advised importing the vaccine from the United States to supplement the tight supply in Europe as the infection rate rises across the bloc.
Earlier in June, the European Union signed an agreement with Bavarian Nordic to supply about 110,000 doses of its monkeypox vaccines.

Leave a Comment